Biofrontera (BFRI) Asset Writedowns and Impairment (2020 - 2025)
Biofrontera's (BFRI) quarterly Asset Writedowns and Impairment came in at -$25000.0 in Q4 2025, down 149.02% year-on-year from $51000.0 in Q4 2024, and down 292.31% quarter-over-quarter from $13000.0 in Q3 2025.
Biofrontera (BFRI) Asset Writedowns and Impairment (2020 - 2025) Analysis & Trends
Biofrontera's Asset Writedowns and Impairment history runs 6 years deep, the most recent figure standing at -$25000.0 for Q4 2025.
- On a quarterly basis, Asset Writedowns and Impairment fell 149.02% year-over-year to -$25000.0 in Q4 2025; TTM through Dec 2025 was -$69000.0, a 142.59% decrease from a year earlier, with the FY2025 full-year figure at -$69000.0, down 142.59% from the prior year.
- Asset Writedowns and Impairment slipped to -$25000.0 in Q4 2025 per BFRI's latest filing, from $13000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $94000.0 in Q3 2023 and bottomed at -$46000.0 in Q1 2025.
- The 5-year median for Asset Writedowns and Impairment is $12000.0 (2022), against an average of $17400.0.
- Biggest YoY gain for Asset Writedowns and Impairment was 5900.0% in 2022; the steepest drop was 650.0% in 2022.
- Year by year, Asset Writedowns and Impairment stood at $2000.0 in 2021, then sank by 650.0% to -$11000.0 in 2022, then plunged by 227.27% to -$36000.0 in 2023, then jumped by 241.67% to $51000.0 in 2024, then slumped by 149.02% to -$25000.0 in 2025.
- Per Business Quant, the three latest BFRI Asset Writedowns and Impairment figures stand at -$25000.0 (Q4 2025), $13000.0 (Q3 2025), and -$11000.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.84 Bn | 32.10 Bn | 1.97 Bn |
| 3 | Zoetis | 32.67 Bn | 30.73 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.69 Bn | 23.63 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.12 Bn | 20.97 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - |
| 7 | Viatris | 20.24 Bn | 18.44 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.83 Bn | 16.51 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.22 Bn | 785.00 Mn |
| 10 | Biofrontera | 10.88 Mn | 4.47 Mn | 14.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -25,000.00 |
| Dec 31, 2025 | -25,000.00 |
| Sep 30, 2025 | 13,000.00 |
| Sep 30, 2025 | 13,000.00 |
| Jun 30, 2025 | -11,000.00 |
| Jun 30, 2025 | -11,000.00 |
| Mar 31, 2025 | -46,000.00 |
| Mar 31, 2025 | -46,000.00 |
| Dec 31, 2024 | 51,000.00 |
| Dec 31, 2024 | 51,000.00 |
| Sep 30, 2024 | 34,000.00 |
| Sep 30, 2024 | 34,000.00 |
| Jun 30, 2024 | 11,000.00 |
| Jun 30, 2024 | 11,000.00 |
| Mar 31, 2024 | 66,000.00 |
| Mar 31, 2024 | 66,000.00 |
| Dec 31, 2023 | -36,000.00 |
| Dec 31, 2023 | -36,000.00 |
| Sep 30, 2023 | 94,000.00 |
| Sep 30, 2023 | 94,000.00 |